Telavancin.

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Agents
• Clinical Microbiology

Background:

• Lipoglycopeptide antibiotics represent a novel class of agents targeting Gram-positive bacteria.
• Meticillin-resistant Staphylococcus aureus (MRSA) poses a significant challenge in complicated skin and skin structure infections (cSSSIs).
• Telavancin is the first approved lipoglycopeptide with demonstrated activity against MRSA.

Purpose of the Study:

• To evaluate the efficacy and safety of telavancin in adult patients with cSSSIs.
• To compare telavancin's effectiveness against Gram-positive pathogens, including MRSA, with vancomycin.
• To assess clinical cure rates at the test-of-cure (TOC) visit.

Main Methods:

• Randomized, double-blind, non-inferiority trials comparing intravenous telavancin (10 mg/kg once daily) with intravenous vancomycin (1 g every 12 hours).
• Inclusion of adult patients diagnosed with cSSSIs, including those with documented MRSA infections.
• Assessment of clinical cure rates across clinically evaluable, all-treated, and microbiologically evaluable populations.

Main Results:

• Telavancin achieved comparable clinical cure rates (88%) to vancomycin (87%) in the pooled clinically evaluable population.
• Efficacy was consistent across all treatment populations and subgroups, including those with MRSA infections.
• Telavancin was generally well-tolerated, with most adverse events reported as mild or moderate.

Conclusions:

• Intravenous telavancin is an effective treatment option for adult patients with cSSSIs, including those caused by MRSA.
• Telavancin demonstrates non-inferior efficacy compared to vancomycin for cSSSIs.
• The favorable safety profile supports telavancin's role in managing Gram-positive bacterial skin infections.